DrugInformations.org

Ankylosing Spondylitis (Bechterew’s Disease) is a painful chronic inflammatory rheumatic disease, associated with stiffening of the vertrebral column. Between 100,000 and 150,000 cases have already been diagnosed in Germany, but milder forms of the disease may remain undiagnosed. The research team, led by Dr. Roland R. Wick, with Dr. Elke A. Nekolla, Prof. Dr. Albrecht M. Kellerer and the late Prof. Dr.

More: continued here

No Comments »

Active Biotech AB’s (OMX Nordic:ACTI) collaboration partner MediGene AG (Frankfurt, Prime Standard: MDG) has achieved its objectives in a clinical phase IIa trial of the candidate drug RhuDex® for the treatment of rheumatoid arthritis. In addition to positive safety data and the good adsorption after oral administration, a first indication of biological activity of RhuDex® was observed.

More: continued here

No Comments »

New data suggest that patients with osteoarthritis pain of the knee treated with 60 mg and 120 mg Cymbalta (duloxetine HCl) once daily experienced significant pain reduction. Patients taking duloxetine reported significant pain improvement compared to placebo within the first week of treatment that lasted throughout the 13-week trial.(1) Results from the study of 231 patients were presented at the annual congress of the European League Against Rheumatism (EULAR) in Paris, France.

More: continued here

No Comments »

Centocor, Inc. announced that a Biologics License Application (BLA) has been submitted to the U.S. Food and Drug Administration (FDA) requesting the approval of golimumab (CNTO 148) as a monthly subcutaneous treatment for adults with active forms of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

More: continued here

No Comments »

In the course of an epidemiological study, scientists of the Institute of Radiation Biology of the Helmholtz Zentrum Munchen German Research Center for Environmental Health have established an unfavourable benefit-risk-ratio for ankylosing spondylitis patients treated with Radium-224 therapy (Rheumatology 2008; 47: 855-59). Ankylosing Spondylitis (Bechterew’s Disease) is a painful chronic inflammatory rheumatic disease, associated with stiffening of the vertrebral column.

More: continued here

No Comments »

According to the National Institutes of Health, nearly 10 million Americans suffer from fibromyalgia. Sadly, many go through months and years of pain, frustration and confusion before receiving treatment because there is no diagnostic for this chronic illness. Medical tests such as x-rays, blood tests and muscle biopsies can rule out other medical conditions (lupus, rheumatoid arthritis, Lyme disease) but can’t confirm fibromyalgia.

More: continued here

No Comments »

PARIS: The interleukin-6 receptor inhibitor Actemra (tocilizumab) achieves significantly greater reduction in the signs and symptoms of rheumatoid arthritis (RA) than the current standard of care, methotrexate, according to two international clinical trials reported this week at EULAR 2008, the Annual European Congress of Rheumatology.

More: continued here

No Comments »

Seniors with osteoarthritis who undergo total hip replacement are twice as likely as those who do not to show improvements in physical functioning and increased ability to care for themselves, according to researchers at Duke University Medical Center.The study, which is the largest of its kind conducted to date, found that there is no age limit on the benefits of hip replacement for patients.

More: continued here

No Comments »

Data presented recently show that 80% of patients with early active rheumatoid arthritis achieved radiographic remission (or non-progression defined as a change in TSS≤0.5) at one year when treated with Enbrel (etanercept) and methotrexate, compared to 59% when treated with methotrexate alone1.

More: continued here

No Comments »

UCB has announced new data showing that Cimzia® (certolizumab pegol), the only PEGylated, Fc-Free anti-TNF (Tumor Necrosis Factor), combined with methotrexate (MTX), significantly inhibits progression of joint damage in patients with active rheumatoid arthritis (RA) as early as 16 weeks after the start of treatment.

More: continued here

No Comments »